Somatic Genetic Testing
Somatic Genetic Testing

Somatic Genetic Testing Comprehensive Study by Type (Product (Kits and Assays, Instruments, and Software), Services), Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors), Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)), Technology (Sequencing (NGS and Traditional Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, Other Technologies), Sample (Tissue-Based, Blood-Based, Bone Marrow Aspirates, Others), End User (Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others) Players and Region - Global Market Outlook to 2026

Somatic Genetic Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 9.8%  

Aug 2021 Edition 229 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Somatic Genetic Testing Market Scope?
The Global Increase in Cancer Prevalence will help to boost the global Somatic Genetic Testing market in the forecasted period. Somatic genetic tests look for gene changes only. Somatic testing is done on cancer cells. It can help doctors learn more about your cancer. Germline testing is done on non-cancer cells. It can show if a genetic change is in all of the cells in your body. Somatic testing is done on cancer cells. It can help doctors learn more about your cancer. Germline testing is done on non-cancer cells. It can show if a genetic change is in all of the cells in your body. Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patient's tumor profile.

The Somatic Genetic Testing market study is being classified by Type (Product (Kits and Assays, Instruments, and Software) and Services), by Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors) and Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)) and major geographies with country level break-up. According to AMA, the Global Somatic Genetic Testing market is expected to see growth rate of 9.8% and may see market size of USD1701.0 Million by 2026.

Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Somatic Genetic Testing market throughout the predicted period.

ARUP Laboratories (United States), ASURAGEN Inc. (United States), Beijing Genomics Institute (BGI) Genomics Co., Ltd (China), bioMerieux S.A. (France), CENTOGENE N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health, Inc. (United States), Illumina, Inc. (United States) and Invivoscribe, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Laboratory Corporation of America Holdings, Mission Bio, NeoGenomics Laboratories, Inc., OmniSeq, Oxford Nanopore Technologies Ltd. and Pacific Biosciences of California, Inc..

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Somatic Genetic Testing market by Type, Application and Region.

On the basis of geography, the market of Somatic Genetic Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Influencers and their development strategies
On 31st May 2021, Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next-Generation Genomics Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, has announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT).
On 22 May 2020 - Roche has announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomic's unique chemistry, Sequencing by Expansion (SBX™).


Influencing Market Trend
  • Decreasing Cost of Sequencing
  • Increasing Adoption of Inorganic Growth Strategies

Market Drivers
  • Global Increase in Cancer Prevalence
  • Increasing Consumer Awareness for Tailored Cancer Therapy

Opportunities
  • Technological Advancements in the Field of Cancer Genomics
  • Massive Scope for Adoption of NGS-based Somatic Genetic Testing in the Emerging Markets

Restraints
  • Uncertain Regulatory and Reimbursement Policies

Challenges
  • Lack of Trained Professionals in the Field of Oncology


Key Target Audience
Somatic Genetic Testing Providers, Government Regulatory Bodies, Private Research Organizations, Government Research Organizations and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Somatic Genetic Testing market expands?
The Global Somatic Genetic Testing market is expected to see a growth of 9.8% during projected year 2020 to 2026.

2. Who are the prominent players of the Global Somatic Genetic Testing market?
The prominent players of Global Somatic Genetic Testing market are ARUP Laboratories (United States), ASURAGEN Inc. (United States), Beijing Genomics Institute (BGI) Genomics Co., Ltd (China), bioMerieux S.A. (France), CENTOGENE N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health, Inc. (United States), Illumina, Inc. (United States) and Invivoscribe, Inc. (United States), to name a few.

3. What are the top priorities to focus for Somatic Genetic Testing market’s growth?
In this highly competitive & fast evolving Somatic Genetic Testing industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Product (Kits and Assays, Instruments, and Software)
  • Services
By Application
  • Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors)
  • Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
By Technology
  • Sequencing (NGS and Traditional Sequencing)
  • Polymerase Chain Reaction (RT-PCR and dPCR)
  • Microarray
  • Other Technologies

By Sample
  • Tissue-Based
  • Blood-Based
  • Bone Marrow Aspirates
  • Others

By End User
  • Academic and Research Institutions
  • Hospitals and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Increase in Cancer Prevalence
      • 3.2.2. Increasing Consumer Awareness for Tailored Cancer Therapy
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals in the Field of Oncology
    • 3.4. Market Trends
      • 3.4.1. Decreasing Cost of Sequencing
      • 3.4.2. Increasing Adoption of Inorganic Growth Strategies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Somatic Genetic Testing, by Type, Application, Technology, Sample, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Somatic Genetic Testing (Value)
      • 5.2.1. Global Somatic Genetic Testing by: Type (Value)
        • 5.2.1.1. Product (Kits and Assays, Instruments, and Software)
        • 5.2.1.2. Services
      • 5.2.2. Global Somatic Genetic Testing by: Application (Value)
        • 5.2.2.1. Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors)
        • 5.2.2.2. Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
      • 5.2.3. Global Somatic Genetic Testing by: Technology (Value)
        • 5.2.3.1. Sequencing (NGS and Traditional Sequencing)
        • 5.2.3.2. Polymerase Chain Reaction (RT-PCR and dPCR)
        • 5.2.3.3. Microarray
        • 5.2.3.4. Other Technologies
      • 5.2.4. Global Somatic Genetic Testing by: Sample (Value)
        • 5.2.4.1. Tissue-Based
        • 5.2.4.2. Blood-Based
        • 5.2.4.3. Bone Marrow Aspirates
        • 5.2.4.4. Others
      • 5.2.5. Global Somatic Genetic Testing by: End User (Value)
        • 5.2.5.1. Academic and Research Institutions
        • 5.2.5.2. Hospitals and Diagnostic Laboratories
        • 5.2.5.3. Pharmaceutical and Biotechnology Companies
        • 5.2.5.4. Contract Research Organizations
        • 5.2.5.5. Others
      • 5.2.6. Global Somatic Genetic Testing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Somatic Genetic Testing (Price)
      • 5.3.1. Global Somatic Genetic Testing by: Type (Price)
  • 6. Somatic Genetic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ARUP Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ASURAGEN Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beijing Genomics Institute (BGI) Genomics Co., Ltd (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioMerieux S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CENTOGENE N.V. (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Guardant Health, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Illumina, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Invivoscribe, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Somatic Genetic Testing Sale, by Type, Application, Technology, Sample, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Somatic Genetic Testing (Value)
      • 7.2.1. Global Somatic Genetic Testing by: Type (Value)
        • 7.2.1.1. Product (Kits and Assays, Instruments, and Software)
        • 7.2.1.2. Services
      • 7.2.2. Global Somatic Genetic Testing by: Application (Value)
        • 7.2.2.1. Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors)
        • 7.2.2.2. Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
      • 7.2.3. Global Somatic Genetic Testing by: Technology (Value)
        • 7.2.3.1. Sequencing (NGS and Traditional Sequencing)
        • 7.2.3.2. Polymerase Chain Reaction (RT-PCR and dPCR)
        • 7.2.3.3. Microarray
        • 7.2.3.4. Other Technologies
      • 7.2.4. Global Somatic Genetic Testing by: Sample (Value)
        • 7.2.4.1. Tissue-Based
        • 7.2.4.2. Blood-Based
        • 7.2.4.3. Bone Marrow Aspirates
        • 7.2.4.4. Others
      • 7.2.5. Global Somatic Genetic Testing by: End User (Value)
        • 7.2.5.1. Academic and Research Institutions
        • 7.2.5.2. Hospitals and Diagnostic Laboratories
        • 7.2.5.3. Pharmaceutical and Biotechnology Companies
        • 7.2.5.4. Contract Research Organizations
        • 7.2.5.5. Others
      • 7.2.6. Global Somatic Genetic Testing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Somatic Genetic Testing (Price)
      • 7.3.1. Global Somatic Genetic Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Somatic Genetic Testing: by Type(USD Million)
  • Table 2. Somatic Genetic Testing Product (Kits and Assays, Instruments, and Software) , by Region USD Million (2015-2020)
  • Table 3. Somatic Genetic Testing Services , by Region USD Million (2015-2020)
  • Table 4. Somatic Genetic Testing: by Application(USD Million)
  • Table 5. Somatic Genetic Testing Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors) , by Region USD Million (2015-2020)
  • Table 6. Somatic Genetic Testing Hematological Malignancies (Leukemia, Lymphoma, and Myeloma) , by Region USD Million (2015-2020)
  • Table 7. Somatic Genetic Testing: by Technology(USD Million)
  • Table 8. Somatic Genetic Testing Sequencing (NGS and Traditional Sequencing) , by Region USD Million (2015-2020)
  • Table 9. Somatic Genetic Testing Polymerase Chain Reaction (RT-PCR and dPCR) , by Region USD Million (2015-2020)
  • Table 10. Somatic Genetic Testing Microarray , by Region USD Million (2015-2020)
  • Table 11. Somatic Genetic Testing Other Technologies , by Region USD Million (2015-2020)
  • Table 12. Somatic Genetic Testing: by Sample(USD Million)
  • Table 13. Somatic Genetic Testing Tissue-Based , by Region USD Million (2015-2020)
  • Table 14. Somatic Genetic Testing Blood-Based , by Region USD Million (2015-2020)
  • Table 15. Somatic Genetic Testing Bone Marrow Aspirates , by Region USD Million (2015-2020)
  • Table 16. Somatic Genetic Testing Others , by Region USD Million (2015-2020)
  • Table 17. Somatic Genetic Testing: by End User(USD Million)
  • Table 18. Somatic Genetic Testing Academic and Research Institutions , by Region USD Million (2015-2020)
  • Table 19. Somatic Genetic Testing Hospitals and Diagnostic Laboratories , by Region USD Million (2015-2020)
  • Table 20. Somatic Genetic Testing Pharmaceutical and Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 21. Somatic Genetic Testing Contract Research Organizations , by Region USD Million (2015-2020)
  • Table 22. Somatic Genetic Testing Others , by Region USD Million (2015-2020)
  • Table 23. South America Somatic Genetic Testing, by Country USD Million (2015-2020)
  • Table 24. South America Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 25. South America Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 26. South America Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 27. South America Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 28. South America Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 29. Brazil Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 30. Brazil Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 31. Brazil Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 32. Brazil Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 33. Brazil Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 34. Argentina Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 35. Argentina Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 36. Argentina Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 37. Argentina Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 38. Argentina Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 39. Rest of South America Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 40. Rest of South America Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 41. Rest of South America Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 42. Rest of South America Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 43. Rest of South America Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 44. Asia Pacific Somatic Genetic Testing, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 46. Asia Pacific Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 47. Asia Pacific Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 48. Asia Pacific Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 49. Asia Pacific Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 50. China Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 51. China Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 52. China Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 53. China Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 54. China Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 55. Japan Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 56. Japan Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 57. Japan Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 58. Japan Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 59. Japan Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 60. India Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 61. India Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 62. India Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 63. India Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 64. India Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 65. South Korea Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 66. South Korea Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 67. South Korea Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 68. South Korea Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 69. South Korea Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 70. Taiwan Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 71. Taiwan Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 72. Taiwan Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 73. Taiwan Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 74. Taiwan Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 75. Australia Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 76. Australia Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 77. Australia Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 78. Australia Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 79. Australia Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 85. Europe Somatic Genetic Testing, by Country USD Million (2015-2020)
  • Table 86. Europe Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 87. Europe Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 88. Europe Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 89. Europe Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 90. Europe Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 91. Germany Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 92. Germany Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 93. Germany Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 94. Germany Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 95. Germany Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 96. France Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 97. France Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 98. France Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 99. France Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 100. France Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 101. Italy Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 102. Italy Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 103. Italy Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 104. Italy Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 105. Italy Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 106. United Kingdom Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 107. United Kingdom Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 108. United Kingdom Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 109. United Kingdom Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 110. United Kingdom Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 111. Netherlands Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 112. Netherlands Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 113. Netherlands Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 114. Netherlands Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 115. Netherlands Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 116. Rest of Europe Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 117. Rest of Europe Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 118. Rest of Europe Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 119. Rest of Europe Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 120. Rest of Europe Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 121. MEA Somatic Genetic Testing, by Country USD Million (2015-2020)
  • Table 122. MEA Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 123. MEA Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 124. MEA Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 125. MEA Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 126. MEA Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 127. Middle East Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 128. Middle East Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 129. Middle East Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 130. Middle East Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 131. Middle East Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 132. Africa Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 133. Africa Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 134. Africa Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 135. Africa Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 136. Africa Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 137. North America Somatic Genetic Testing, by Country USD Million (2015-2020)
  • Table 138. North America Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 139. North America Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 140. North America Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 141. North America Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 142. North America Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 143. United States Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 144. United States Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 145. United States Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 146. United States Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 147. United States Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 148. Canada Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 149. Canada Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 150. Canada Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 151. Canada Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 152. Canada Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 153. Mexico Somatic Genetic Testing, by Type USD Million (2015-2020)
  • Table 154. Mexico Somatic Genetic Testing, by Application USD Million (2015-2020)
  • Table 155. Mexico Somatic Genetic Testing, by Technology USD Million (2015-2020)
  • Table 156. Mexico Somatic Genetic Testing, by Sample USD Million (2015-2020)
  • Table 157. Mexico Somatic Genetic Testing, by End User USD Million (2015-2020)
  • Table 158. Somatic Genetic Testing: by Type(USD/Units)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Somatic Genetic Testing: by Type(USD Million)
  • Table 169. Somatic Genetic Testing Product (Kits and Assays, Instruments, and Software) , by Region USD Million (2021-2026)
  • Table 170. Somatic Genetic Testing Services , by Region USD Million (2021-2026)
  • Table 171. Somatic Genetic Testing: by Application(USD Million)
  • Table 172. Somatic Genetic Testing Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors) , by Region USD Million (2021-2026)
  • Table 173. Somatic Genetic Testing Hematological Malignancies (Leukemia, Lymphoma, and Myeloma) , by Region USD Million (2021-2026)
  • Table 174. Somatic Genetic Testing: by Technology(USD Million)
  • Table 175. Somatic Genetic Testing Sequencing (NGS and Traditional Sequencing) , by Region USD Million (2021-2026)
  • Table 176. Somatic Genetic Testing Polymerase Chain Reaction (RT-PCR and dPCR) , by Region USD Million (2021-2026)
  • Table 177. Somatic Genetic Testing Microarray , by Region USD Million (2021-2026)
  • Table 178. Somatic Genetic Testing Other Technologies , by Region USD Million (2021-2026)
  • Table 179. Somatic Genetic Testing: by Sample(USD Million)
  • Table 180. Somatic Genetic Testing Tissue-Based , by Region USD Million (2021-2026)
  • Table 181. Somatic Genetic Testing Blood-Based , by Region USD Million (2021-2026)
  • Table 182. Somatic Genetic Testing Bone Marrow Aspirates , by Region USD Million (2021-2026)
  • Table 183. Somatic Genetic Testing Others , by Region USD Million (2021-2026)
  • Table 184. Somatic Genetic Testing: by End User(USD Million)
  • Table 185. Somatic Genetic Testing Academic and Research Institutions , by Region USD Million (2021-2026)
  • Table 186. Somatic Genetic Testing Hospitals and Diagnostic Laboratories , by Region USD Million (2021-2026)
  • Table 187. Somatic Genetic Testing Pharmaceutical and Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 188. Somatic Genetic Testing Contract Research Organizations , by Region USD Million (2021-2026)
  • Table 189. Somatic Genetic Testing Others , by Region USD Million (2021-2026)
  • Table 190. South America Somatic Genetic Testing, by Country USD Million (2021-2026)
  • Table 191. South America Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 192. South America Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 193. South America Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 194. South America Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 195. South America Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 196. Brazil Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 197. Brazil Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 198. Brazil Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 199. Brazil Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 200. Brazil Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 201. Argentina Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 202. Argentina Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 203. Argentina Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 204. Argentina Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 205. Argentina Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 206. Rest of South America Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 207. Rest of South America Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 208. Rest of South America Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 209. Rest of South America Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 210. Rest of South America Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 211. Asia Pacific Somatic Genetic Testing, by Country USD Million (2021-2026)
  • Table 212. Asia Pacific Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 213. Asia Pacific Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 214. Asia Pacific Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 215. Asia Pacific Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 216. Asia Pacific Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 217. China Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 218. China Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 219. China Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 220. China Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 221. China Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 222. Japan Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 223. Japan Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 224. Japan Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 225. Japan Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 226. Japan Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 227. India Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 228. India Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 229. India Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 230. India Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 231. India Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 232. South Korea Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 233. South Korea Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 234. South Korea Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 235. South Korea Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 236. South Korea Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 237. Taiwan Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 238. Taiwan Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 239. Taiwan Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 240. Taiwan Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 241. Taiwan Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 242. Australia Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 243. Australia Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 244. Australia Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 245. Australia Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 246. Australia Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 252. Europe Somatic Genetic Testing, by Country USD Million (2021-2026)
  • Table 253. Europe Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 254. Europe Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 255. Europe Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 256. Europe Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 257. Europe Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 258. Germany Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 259. Germany Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 260. Germany Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 261. Germany Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 262. Germany Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 263. France Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 264. France Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 265. France Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 266. France Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 267. France Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 268. Italy Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 269. Italy Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 270. Italy Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 271. Italy Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 272. Italy Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 273. United Kingdom Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 274. United Kingdom Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 275. United Kingdom Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 276. United Kingdom Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 277. United Kingdom Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 278. Netherlands Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 279. Netherlands Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 280. Netherlands Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 281. Netherlands Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 282. Netherlands Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 283. Rest of Europe Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 284. Rest of Europe Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 285. Rest of Europe Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 286. Rest of Europe Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 287. Rest of Europe Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 288. MEA Somatic Genetic Testing, by Country USD Million (2021-2026)
  • Table 289. MEA Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 290. MEA Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 291. MEA Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 292. MEA Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 293. MEA Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 294. Middle East Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 295. Middle East Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 296. Middle East Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 297. Middle East Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 298. Middle East Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 299. Africa Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 300. Africa Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 301. Africa Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 302. Africa Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 303. Africa Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 304. North America Somatic Genetic Testing, by Country USD Million (2021-2026)
  • Table 305. North America Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 306. North America Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 307. North America Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 308. North America Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 309. North America Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 310. United States Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 311. United States Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 312. United States Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 313. United States Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 314. United States Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 315. Canada Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 316. Canada Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 317. Canada Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 318. Canada Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 319. Canada Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 320. Mexico Somatic Genetic Testing, by Type USD Million (2021-2026)
  • Table 321. Mexico Somatic Genetic Testing, by Application USD Million (2021-2026)
  • Table 322. Mexico Somatic Genetic Testing, by Technology USD Million (2021-2026)
  • Table 323. Mexico Somatic Genetic Testing, by Sample USD Million (2021-2026)
  • Table 324. Mexico Somatic Genetic Testing, by End User USD Million (2021-2026)
  • Table 325. Somatic Genetic Testing: by Type(USD/Units)
  • Table 326. Research Programs/Design for This Report
  • Table 327. Key Data Information from Secondary Sources
  • Table 328. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Somatic Genetic Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Somatic Genetic Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Somatic Genetic Testing: by Technology USD Million (2015-2020)
  • Figure 7. Global Somatic Genetic Testing: by Sample USD Million (2015-2020)
  • Figure 8. Global Somatic Genetic Testing: by End User USD Million (2015-2020)
  • Figure 9. South America Somatic Genetic Testing Share (%), by Country
  • Figure 10. Asia Pacific Somatic Genetic Testing Share (%), by Country
  • Figure 11. Europe Somatic Genetic Testing Share (%), by Country
  • Figure 12. MEA Somatic Genetic Testing Share (%), by Country
  • Figure 13. North America Somatic Genetic Testing Share (%), by Country
  • Figure 14. Global Somatic Genetic Testing: by Type USD/Units (2015-2020)
  • Figure 15. Global Somatic Genetic Testing share by Players 2020 (%)
  • Figure 16. Global Somatic Genetic Testing share by Players (Top 3) 2020(%)
  • Figure 17. Global Somatic Genetic Testing share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. ARUP Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. ARUP Laboratories (United States) Revenue: by Geography 2020
  • Figure 21. ASURAGEN Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. ASURAGEN Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Beijing Genomics Institute (BGI) Genomics Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 24. Beijing Genomics Institute (BGI) Genomics Co., Ltd (China) Revenue: by Geography 2020
  • Figure 25. BioMerieux S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. BioMerieux S.A. (France) Revenue: by Geography 2020
  • Figure 27. CENTOGENE N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 28. CENTOGENE N.V. (Germany) Revenue: by Geography 2020
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 31. Guardant Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Guardant Health, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Illumina, Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Invivoscribe, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Invivoscribe, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Somatic Genetic Testing: by Type USD Million (2021-2026)
  • Figure 38. Global Somatic Genetic Testing: by Application USD Million (2021-2026)
  • Figure 39. Global Somatic Genetic Testing: by Technology USD Million (2021-2026)
  • Figure 40. Global Somatic Genetic Testing: by Sample USD Million (2021-2026)
  • Figure 41. Global Somatic Genetic Testing: by End User USD Million (2021-2026)
  • Figure 42. South America Somatic Genetic Testing Share (%), by Country
  • Figure 43. Asia Pacific Somatic Genetic Testing Share (%), by Country
  • Figure 44. Europe Somatic Genetic Testing Share (%), by Country
  • Figure 45. MEA Somatic Genetic Testing Share (%), by Country
  • Figure 46. North America Somatic Genetic Testing Share (%), by Country
  • Figure 47. Global Somatic Genetic Testing: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • ARUP Laboratories (United States)
  • ASURAGEN Inc. (United States)
  • Beijing Genomics Institute (BGI) Genomics Co., Ltd (China)
  • bioMerieux S.A. (France)
  • CENTOGENE N.V. (Germany)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Guardant Health, Inc. (United States)
  • Illumina, Inc. (United States)
  • Invivoscribe, Inc. (United States)
Additional players considered in the study are as follows:
Laboratory Corporation of America Holdings , Mission Bio , NeoGenomics Laboratories, Inc. , OmniSeq , Oxford Nanopore Technologies Ltd. , Pacific Biosciences of California, Inc.
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation